Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the ...

SCAI Stage C cardiogenic shock is characterized by significant organ hypoperfusion, necessitating the use of inotropic or vasopressor drugs. However, these medications are often accompanied by ...

This study follows the positive results in both SEISMiC A and B in SCAI Stage B cardiogenic shock trials. In these trials, istaroxime improved systolic blood pressure, cardiac function and renal ...

SCAI's SHOCK classification identifies Stage B CS as beginning or early CS, wherein the cardiac dysfunction has not yet fully manifested itself. SCAI B CS was defined as hypotension (systolic ...

today announced it is targeting the planned interim analysis results for the istaroxime cardiogenic shock SEISMiC SCAI Stage C Phase 2 study (the “SEISMiC C Study”) for July 2025. The SEISMiC ...

After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient ...

After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient ...